Tirofiban vs standard antiplatelet therapy in acute branch atheromatous disease-related stroke: a multicenter, randomized, open-label, blinded-endpoint, parallel-group, phase III clinical trial

The Lancet Regional Health - Western Pacific · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles